Business

Novo Nordisk adopts ‘Novo’ identity and new culture framework to sharpen competitiveness

Novo Nordisk adopts ‘Novo’ identity and new culture framework to sharpen competitiveness

Novo Nordisk (Nasdaq: NVO) is simplifying its public identity to "Novo" and adopting a new operating culture framework, moves the Denmark-based company said are designed to sharpen its competitive position as the healthcare market becomes faster-moving and more consumer-driven.

The rebrand, announced on September 14, centers on the tagline "Lasting Health Starts Now" and retains the Apis bull logo from the company's heritage while updating its visual identity. Novo Nordisk A/S remains the legal corporate name, but "Novo" will be used in day-to-day contexts. The company said the simplified name is intended to improve recognition and consistency across medicines, partnerships, and stakeholder engagement globally.

Running alongside the rebrand is "The Novo Way," a cultural framework built around four principles: customer obsession, competitiveness, clarity, and care and integrity. The company described it as an effort to build on existing organizational strengths — scientific expertise, patient safety, and long-term commitment — while embedding the behaviors needed to operate with greater speed and decisiveness. President and CEO Mike Doustdar said healthcare must become "more responsive, relevant and easier to fit into everyday life," framing both the brand and culture changes as strategic enablers rather than cosmetic updates.

Executive vice president for People, Organisation and Corporate Affairs Tania Sabroe said the two initiatives are intended to work in tandem: culture shaping internal execution and brand shaping external perception. The company employs more than 67,000 people worldwide.

The AllSci BriefFree, systematic R&D and deal news. Daily.

The announcement comes one week before Novo's Capital Markets Day, scheduled for September 21 in London, where the company said it will provide a detailed overview of its updated corporate strategy.

Novo has built its commercial position predominantly in diabetes and obesity, where its glucagon-like peptide-1 receptor agonist portfolio — including semaglutide (Ozempic, Wegovy) — has driven revenue growth. The company faces intensifying competition in both categories from Eli Lilly, whose tirzepatide (Mounjaro, Zepbound) has taken meaningful market share, as well as from a growing field of next-generation cardiometabolic candidates in development across the industry. The rebrand and cultural reset come as Novo seeks to regain competitive momentum against Eli Lilly and prepare investors for a broader strategy update at its September 21 Capital Markets Day.


Spot something wrong? Report an issue with this article